TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00876902

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Viaspan® and saline
Description: Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of \>10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
Study: NCT03906110

Intervention type: BEHAVIORAL
Intervention: Contact Message
Description: Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.

Intervention type: BEHAVIORAL
Intervention: Contact Message
Description: Card with a general message about colorectal cancer screening. This same message will be delivered at 3 time points.
Study: NCT03911557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab and Tremelimumab
Description: Durvalumab 1500mg + tremelimumab 75mg via IV infusion Q4W, starting on Week 1, for up to a maximum of 4 doses/cycles followed by durvalumab monotherapy 1500 mg via IV infusion Q4W, starting 4 weeks after the last infusion of the combination, for up to a maximum of 2 years of total therapy.
Study: NCT03906110

Intervention type: BEHAVIORAL
Intervention: Personalized One on One Education
Description: * Trained study coordinators will meet with participant for a brief 15 minute educational session delivered in clinic that summarizes information from the materials and demonstrates FIT collection.~* Email or text reminders with brief messages in clear language will be sent that aim to remind and prompt patients to complete FIT.~* For participants that are not responsive to above, trained study staff will address specific FIT specific hinderances by telephone or in clinic.~* Participants will receive a one page summary of key points of salience of repeat screening GET FIT AGAIN. Another FIT kit is provided.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Immunochemical Test (FIT)
Description: The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Immunochemical Test (FIT)
Description: The Fecal Immunochemical Test (FIT), is a screening test that detects hemoglobin in stool samples, only requiring one stool sample.
Study: NCT02633787

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Description: No vaccine will be administered in this trial
Study: NCT02684994

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Processing Therapy
Description: Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
Study: NCT02678208

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5% glucose

Intervention type: DRUG
Group type: OTHER
Intervention: 5% glucose
Study: NCT03741257

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: resuscitation fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: resuscitation fluid
Study: NCT03103724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xtandi
Description: Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
Study: NCT03937739

Intervention type: OTHER
Intervention: Nutritional and constipation questionnaire
Description: Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire

Intervention type: OTHER
Intervention: Nutritional and constipation questionnaire
Description: Alcohol and smoking habits, daily activity, frequency of food consumption and the constipation scoring according to Agachan et all. were examined using questionnaire
Study: NCT02215915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Angiography
Description: The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IVUS
Description: The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
Study: NCT01667666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebulized hypertonic saline
Description: The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
Study: NCT01652014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV over 1 hour on Day -6; after pre-hydration
Study: NCT02215915

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DES implantation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DES implantation
Study: NCT02114905

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OTs Trained and Deliver CBIT
Description: CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily.
Study: NCT03602911

Intervention type: DRUG
Group type: OTHER
Intervention: The isotope 68Ga, NETSPOT and 18F-FDG-PET/CT
Description: All patients will undergo 18F-FDG-PET/CT per established protocol. Following 18F-FDG-PET/CT, the patient will undergo NETSPOT imaging
Study: NCT01256593

Intervention type: DRUG
Intervention: Pregabalin (Lyrica) capsule
Description: Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily.
Study: NCT03398720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1066 dose level 1
Description: Starting dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1066 dose level 2
Description: 2nd dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1066 dose level 3
Description: 3rd dose level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTI-1066 dose level 4
Description: 4th dose level
Study: NCT02896972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy with inverted ILM technique or ILM peeling

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vitrectomy
Description: Vitrectomy with inverted ILM technique or ILM peeling
Study: NCT00535119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT02499705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose
Description: 2 packets

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: equisweet to sucralose
Study: NCT02569268

Intervention type: OTHER
Intervention: Questionnaires and follow-up
Description: Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
Study: NCT01129219

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength training
Description: Strength training for 24 weeks
Study: NCT02499705

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sucralose + maltodextrin
Description: sucralose plus equicaloric (to sucrose) maltodextrin
Study: NCT01874444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.
Study: NCT01832571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Once daily Truvada®
Description: At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
Study: NCT02755285

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Endoscopy Procedure
Description: All subjects will have 1 endoscopy procedure, in which they will have a white light examination followed by FICE and BLI imaging on a maximum of two (2) anatomical sites per subject.
Study: NCT04435951

Intervention type: OTHER
Intervention: Evaluation
Description: No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.

Intervention type: OTHER
Intervention: Evaluation
Description: No attempt was made to the individuals in Group 1 and Group 2. Individuals were only evaluated.
Study: NCT01681004

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iFuse Implant System
Description: Placement of iFuse implant system via surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical management
Description: Medications for pain, physical therapy, SI joint injection and RF ablation
Study: NCT02082743

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Outdoor activity in recess time
Description: Outdoor activity in recess time
Study: NCT02569996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
Study: NCT03822390

Intervention type: DEVICE
Intervention: CAD-CNN system
Description: The CAD-CNN system will be trained in predicting the histology of diminutive polyps. Before training, the dataset will be split up into a training set and a test set. To ensure a completely independent test and training set there will be no overlap between patients (i.e. if polyps from a patient A is present in the training set it cannot be in the test set as well).
Study: NCT03243201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colloidal silver nanoparticles
Description: Contains 10ppm colloidal silver nanoparticles

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Purified Water
Description: Purified water will be given as placebo
Study: NCT03480334

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nivolumab plus radiotherapy
Description: Nivolumab 240 mg i.v. at 2-weekly intervals combined with 20Gy radiotherapy (RT) to a preferably progressive and not pre-irradiated single lesion. Nivolumab will be continued for a maximum of 18 months or until disease progression or unacceptable toxicity.
Study: NCT01531049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine cutaneous patch 15mg/16h
Description: One patch for 16hours/day and duration of 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine cutaneous patch 10mg/16h
Description: One patch 16hours/day and duration of 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nicotine cutaneous patch 10mg/16h
Description: One patch 16hours/day and duration of 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cutaneous patch
Description: No active medication.O ne patch 16hours and duration for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cutaneous patch
Description: No active medication.O ne patch 16hours and duration for 8 weeks
Study: NCT04028284

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HoloLens-guided epidural
Description: To determine whether using the HoloLens tool increases the success of epidural insertion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US-guided epidural
Description: traditional thoracic epidural procedure
Study: NCT04458285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacubitril / Valsartan Oral Tablet [Entresto]
Description: Patients in experimental group will receive sacubitril/valsartan with the recommended starting dose: 50mg twice daily (if previous ACEI, ensure 36-hour washout period), after 2-4 weeks, the dose will be doubled to the target maintenance dose of 100mg twice daily(if tolerated) for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80mg Tablet
Description: Patients in active comparator group will receive Valsartan with an dose of 80 mg once daily.
Study: NCT01096797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: * Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.~* Anaesthesia maintenance: sevoflurane 2-3 %~* Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg~* Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg
Study: NCT03916705

Intervention type: OTHER
Group type: OTHER
Intervention: High Velocity Low amplitude spinal manipulation (HVLA-SM)
Description: HVLA-SM is a commonly used spinal manipulation treatment for patients with chronic low back pain.
Study: NCT02539966

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Description: Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Description: Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold
Description: Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
Study: NCT02522923

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapist
Description: The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Provider
Description: The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
Study: NCT04433338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 14-day Low Calorie Diet
Description: Participants will be asked to:~* Use 4 (women) or 5 (men) Modifast meal replacements per day.~* Daily consume a minimum of 250 grams of (raw) vegetables without dressing.~* Daily consume 100 grams of lean meat/fish/meat analogues.~* Daily consume two spoons of liquid oil~* Daily drink at least 2.0 litres of water, coffee or tea without added sugar or milk, bouillon or sugar-free drinks.
Study: NCT05547997

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Stretching exercises
Description: Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretching exercises
Description: Exercises will be performed in the following order: 1) stretching towards lateral flexion for the upper part of the trapezius; 2) ipsilateral flexion and rotation for the scalene; 3) and flexion for the extensor muscles. Each maneuver will be held for 30 seconds as this is an optimum time to not create alteration in the evoked protentional. Each stretch will be repeated 3 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two way traction
Description: During the traction, the head halter will be fixed posteriorly to cause slight distraction, retraction, and slight extension and at the same time a front anterior strap had weight will be applied over a pulley that allows transverse traction load to be applied to the apex of the participants cervical curve alteration. Weights will start at 15 lbs. (6.8 Kg) on the anterior strap and will increase over consecutive visits to patient tolerance or a maximum of 35 lbs. (15.9 Kg).
Study: NCT00727103

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
Study: NCT04530955

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prometra II Programmable Pump - Flowonix Medical
Description: The valve gated Prometra II Programmable Pump will be replacing the prior peristaltic Synchromed II pump and a 20% dose decrease will be performed at the time of the replacement.
Study: NCT01108783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bilastine
Description: 20 mg (encapsulated) tablets QD/14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: 5 mg (encapsulated) tablets QD/14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: (encapsulated) Tablets QD/14 days
Study: NCT01320293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Description: 40mg subcutaneously, every other week for 6 months
Study: NCT01874444

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3
Description: repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 4
Description: Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.~Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS.
Study: NCT01799824

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANT-1403

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01364025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: uterosacral ligament suspension colpopexy bilateral
Description: Uterosacral ligament suspension colpopexy bilateral
Study: NCT03643861

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5 Fraction Stereotactic Body Radiation Therapy
Description: Stereotactic body radiation therapy (SBRT) has gained favor in the treatment of select central nervous system, lung, and abdominal malignancies due to its ability to deliver highly conformal doses of radiotherapy while using sharp dose gradients to deliver comparatively lower doses to the surrounding normal tissue. Utilization of SBRT is more labor intensive than conventional fractionation and requires precise immobilization and localization techniques with daily image guidance with direct physician and physicist oversight for all treatments. While more labor intensive and often utilizing more advanced technologies, SBRT allows the advantage of reducing setup margins compared to conventionally fractionated treatment while being able to shorten overall treatment times due to the ability to safely dose escalate high risk areas
Study: NCT03659214

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Answering 4 questionnaires : anxiety, depression, quality of life and adherence

Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Answering 4 questionnaires : anxiety, depression, quality of life and adherence
Study: NCT01491360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LaserACE(R)
Description: Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.